The first half of 2025 has brought major developments in gastroenterology, spanning new drug approvals, trial data, and clinical guidance. Two major FDA approvals expanded the use of IL-23-targeted therapies in Crohn’s disease: mirikizumab (Omvoh) and guselkumab (Tremfya), both showing strong clinical efficacy across trials.
Trending
- AI-Assisted Colonoscopy and the Diminutive Adenoma Dilemma (Los Angeles Times)
- BE Surveillance, Outpatient ESD, and More (GI & Endoscopy News)
- HHS-OIG Issues Favorable Advisory Opinion for Free Multi-Cancer Detection Supplemental Reports Provided with Medicare-Covered Colorectal Cancer Screening Tests (The National Law Review)
- Physician–researcher’s work yields landmark five-year data for Crohn’s disease drug (Medical Xpress)
- CU Anschutz Biobank Partners with Tech Company to Advance Gut Research and Patient Care (The Regents of the University of Colorado)
- Novant Health adds leading gastroenterology clinicians to its Lowcountry network (Novant Health)
- Solutions Emerging for Post-GLP-1 Weight Regain (Medscape)
- CMS Grants Medicare Coverage for ColoSense®, Expanding Access to Simplified Noninvasive Colorectal Cancer Screening (Business Wire)
